Orchestra BioMed Holdings (OBIO) Profit After Tax (QoQ) (2021 - 2026)

Orchestra BioMed Holdings (OBIO) Profit After Tax (QoQ) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,831.58 Bn 66,831.30 Bn -
2 Nanobiotix 1,916.61 Bn 1,916.55 Bn -
3 Akari Therapeutics 976.78 Bn 976.78 Bn -
4 BeOne Medicines 471.48 Bn 466.69 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.78 Bn 114.53 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.87 Bn 61.12 Bn 3.31 Bn
7 Belite Bio 63.06 Bn 63.06 Bn -
8 Argenx Se 55.78 Bn 50.60 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.54 Bn 34.53 Bn 959.66 Mn
10 Orchestra BioMed Holdings 239.60 Mn 145.20 Mn 78,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -430.53%
Dec 31, 2025 130.10%
Sep 30, 2025 -7.42%
Jun 30, 2025 -3.24%
Mar 31, 2025 -15.32%
Dec 31, 2024 -6.26%
Sep 30, 2024 4.22%
Jun 30, 2024 -18.70%
Mar 31, 2024 -5.03%
Dec 31, 2023 3.60%
Sep 30, 2023 -10.39%
Jun 30, 2023 -10.11%
Mar 31, 2023 -12.21%
Dec 31, 2022 5.17%
Sep 30, 2022 -31.03%
Jun 30, 2022 -36.97%
Mar 31, 2022 -6,409.41%
Dec 31, 2021 2.65%
Sep 30, 2021 2.08%
Jun 30, 2021 14.51%